MXCT
MaxCyte, Inc.
Price Chart
Latest Quote
$1.18
-0.00 (-0.42%)
Current Price
| Previous Close | $1.18 |
| Open | $1.16 |
| Day High | $1.23 |
| Day Low | $1.16 |
| Volume | 754,761 |
Stock Information
| Shares Outstanding | 107.12M |
| Total Debt | $17.49M |
| Cash Equivalents | $106.85M |
| Revenue | $32.29M |
| Net Income | $-39.12M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $125.87M |
| EPS (TTM) | $-0.36 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $36.50M |
| Sales | $32.29M |
| Income | $-39.12M |
| Book/sh | $1.57 |
| Cash/sh | $1.00 |
| Employees | 91 |
Financial Ratios
| Quick Ratio | 10.88 |
| Current Ratio | 12.04 |
| Debt/Eq | 10.42 |
Returns & Margins
| ROA | -11.32% |
| ROE | -21.30% |
| Gross Margin | 80.51% |
| Operating Margin | -64.09% |
| Profit Margin | -121.16% |
Ownership
| Insider Ownership | 1.54% |
| Institutional Ownership | 67.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.72 |
| P/S | 3.90 |
| P/B | 0.75 |
Analyst Data
| Recommendation | none |
| Target Price | $4.11 |
Technical Indicators
| SMA20 | $1.16 |
| SMA50 | $1.01 |
| SMA200 | $1.21 |
| RSI | 44.44 |
| ATR | 0.0704 |
| Shares Float | 97.67M |
| Short Float | 4.22% |
| Short Ratio | 3.80 |
| Volatility | 1.67 |
| Rel Volume | 0.83 |
Performance History
| Week | +1.29% |
| Month | +10.85% |
| Quarter | +55.22% |
| 6 Months | -22.70% |
| YTD | -24.19% |
| Year | -42.40% |
| 3 Years | -76.64% |
| 10 Years | -93.09% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.17 | 756,600 |
| 2026-06-22 | $1.18 | 763,100 |
| 2026-06-18 | $1.21 | 1,773,600 |
| 2026-06-17 | $1.13 | 341,300 |
| 2026-06-16 | $1.14 | 563,600 |
| 2026-06-15 | $1.16 | 434,800 |
| 2026-06-12 | $1.12 | 491,100 |
| 2026-06-11 | $1.10 | 854,000 |
| 2026-06-10 | $1.15 | 597,200 |
| 2026-06-09 | $1.19 | 537,700 |
| 2026-06-08 | $1.15 | 608,700 |
| 2026-06-05 | $1.14 | 900,700 |
| 2026-06-04 | $1.23 | 701,000 |
| 2026-06-03 | $1.20 | 899,800 |
| 2026-06-02 | $1.23 | 942,500 |
| 2026-06-01 | $1.22 | 1,171,100 |
| 2026-05-29 | $1.21 | 1,302,100 |
| 2026-05-28 | $1.17 | 2,090,400 |
| 2026-05-27 | $1.08 | 1,188,500 |
| 2026-05-26 | $1.00 | 1,370,800 |
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
đ° Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga âĸ 2026-05-13T17:06:16Z
Hereâs Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors
Insider Monkey âĸ 2026-05-13T09:27:02Z
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
Benzinga âĸ 2026-05-13T08:14:25Z
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...
GuruFocus.com âĸ 2026-05-13T05:01:48ZMaxCyte Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T01:09:08Z
MaxCyte, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T00:53:09Z
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-12T21:40:04Z
MaxCyte, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-25T12:30:00Z
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...
GuruFocus.com âĸ 2026-03-25T03:01:45ZMaxCyte (MXCT) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-24T21:49:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,306,000 | $6,453,000 | $4,161,000 | $4,928,000 |
| Cost Of Revenue | $6,222,000 | $7,100,000 | $4,742,000 | $5,098,000 |
| Total Revenue | $33,026,000 | $38,627,000 | $41,288,000 | $44,261,000 |
| Operating Revenue | $33,026,000 | $38,627,000 | $41,288,000 | $44,261,000 |
| Expenses | ||||
| Total Expenses | $78,311,000 | $89,824,000 | $89,587,000 | $71,622,000 |
| Other Income Expense | $-6,612,000 | - | - | $-127,000 |
| Net Non Operating Interest Income Expense | $7,267,000 | $10,142,000 | $10,376,000 | $3,917,000 |
| Operating Expense | $72,089,000 | $82,724,000 | $84,845,000 | $66,524,000 |
| Selling And Marketing Expense | $18,924,000 | $26,661,000 | $26,975,000 | $18,653,000 |
| General And Administrative Expense | $28,116,000 | $29,693,000 | $30,068,000 | $25,829,000 |
| Interest Expense | - | - | - | $126,900 |
| Other Non Operating Income Expenses | - | - | - | $-127,000 |
| Interest Expense Non Operating | - | - | - | $126,900 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Net Interest Income | $7,267,000 | $10,142,000 | $10,376,000 | $3,917,000 |
| Interest Income | $7,267,000 | $10,142,000 | $10,376,000 | $3,917,000 |
| Normalized Income | $-38,018,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Net Income From Continuing And Discontinued Operation | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Total Operating Income As Reported | $-51,897,000 | $-51,197,000 | $-48,299,000 | $-27,361,000 |
| Net Income Common Stockholders | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Net Income | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Net Income Including Noncontrolling Interests | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Net Income Continuous Operations | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Pretax Income | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Special Income Charges | $-6,612,000 | $0 | - | - |
| Interest Income Non Operating | $7,267,000 | $10,142,000 | $10,376,000 | $3,917,000 |
| Operating Income | $-45,285,000 | $-51,197,000 | $-48,299,000 | $-27,361,000 |
| Depreciation Amortization Depletion Income Statement | $4,226,000 | $4,143,000 | $3,985,000 | $2,528,000 |
| Depreciation And Amortization In Income Statement | $4,226,000 | $4,143,000 | $3,985,000 | $2,528,000 |
| Gross Profit | $26,804,000 | $31,527,000 | $36,546,000 | $39,163,000 |
| Per Share | ||||
| Diluted EPS | $-0.42 | $-0.39 | $-0.37 | $-0.23 |
| Basic EPS | $-0.42 | $-0.39 | $-0.37 | $-0.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-33,531,000 | $-46,407,000 | $-43,733,000 | $-24,663,000 |
| Total Unusual Items | $-6,612,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-6,612,000 | $0 | - | - |
| Reconciled Depreciation | $5,142,000 | $4,790,000 | $4,566,000 | $2,698,000 |
| EBITDA (Bullshit earnings) | $-40,143,000 | $-46,407,000 | $-43,733,000 | $-24,663,000 |
| EBIT | $-45,285,000 | $-51,197,000 | $-48,299,000 | $-27,361,000 |
| Diluted Average Shares | $106,427,854 | $104,849,222 | $103,268,502 | $101,702,664 |
| Basic Average Shares | $106,427,854 | $104,849,222 | $103,268,502 | $101,702,664 |
| Diluted NI Availto Com Stockholders | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $3,554,000 | $0 | - | - |
| Restructuring And Mergern Acquisition | $3,058,000 | $0 | - | - |
| Research And Development | $20,823,000 | $22,227,000 | $23,817,000 | $19,514,000 |
| Selling General And Administration | $47,040,000 | $56,354,000 | $57,043,000 | $44,482,000 |
| Other Gand A | $28,116,000 | $29,693,000 | $30,068,000 | $25,829,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $170,840,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Total Assets | $202,507,000 | $239,470,000 | $268,274,000 | $286,653,000 |
| Total Non Current Assets | $84,138,000 | $67,786,000 | $78,080,000 | $34,387,000 |
| Other Non Current Assets | $2,467,000 | $1,532,000 | $388,000 | $809,000 |
| Investmentin Financial Assets | $52,570,000 | $35,781,000 | $42,938,000 | $0 |
| Goodwill And Other Intangible Assets | $650,000 | $0 | - | - |
| Other Intangible Assets | $650,000 | - | - | - |
| Current Assets | $118,369,000 | $171,684,000 | $190,194,000 | $252,266,000 |
| Other Current Assets | $4,275,000 | $3,606,000 | $3,899,000 | $3,258,000 |
| Inventory | $7,547,000 | $8,914,000 | $12,229,000 | $8,581,000 |
| Receivables | $3,503,000 | $4,682,000 | $5,778,000 | $13,087,000 |
| Accounts Receivable | $3,503,000 | $4,682,000 | $5,778,000 | $13,087,000 |
| Cash Cash Equivalents And Short Term Investments | $103,044,000 | $154,482,000 | $168,288,000 | $227,340,000 |
| Cash And Cash Equivalents | $20,065,000 | $27,884,000 | $46,506,000 | $11,065,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $17,943,000 | $18,034,000 | $18,743,000 | $16,095,000 |
| Long Term Debt And Capital Lease Obligation | $16,487,000 | $17,170,000 | $17,969,000 | $15,938,000 |
| Current Debt And Capital Lease Obligation | $1,456,000 | $864,000 | $774,000 | $157,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $31,017,000 | $33,219,000 | $36,107,000 | $32,685,000 |
| Total Non Current Liabilities Net Minority Interest | $16,750,000 | $17,444,000 | $18,252,000 | $17,258,000 |
| Other Non Current Liabilities | $263,000 | $274,000 | $283,000 | $1,320,000 |
| Current Liabilities | $14,267,000 | $15,775,000 | $17,855,000 | $15,427,000 |
| Current Deferred Liabilities | $3,598,000 | $5,251,000 | $5,069,000 | $6,713,000 |
| Payables And Accrued Expenses | $9,213,000 | $9,660,000 | $12,012,000 | $8,557,000 |
| Payables | $1,401,000 | $1,358,000 | $743,000 | $292,000 |
| Accounts Payable | $1,401,000 | $1,358,000 | $743,000 | $292,000 |
| Equity | ||||
| Common Stock Equity | $171,490,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Total Equity Gross Minority Interest | $171,490,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Stockholders Equity | $171,490,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Retained Earnings | $-261,483,000 | $-216,853,000 | $-175,798,000 | $-137,875,000 |
| Other | ||||
| Ordinary Shares Number | $106,789,618 | $105,711,093 | $103,961,670 | $102,397,913 |
| Share Issued | $106,789,618 | $105,711,093 | $103,961,670 | $102,397,913 |
| Tangible Book Value | $170,840,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Invested Capital | $171,490,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Working Capital | $104,102,000 | $155,909,000 | $172,339,000 | $236,839,000 |
| Capital Lease Obligations | $17,943,000 | $18,034,000 | $18,743,000 | $16,095,000 |
| Total Capitalization | $171,490,000 | $206,251,000 | $232,167,000 | $253,968,000 |
| Additional Paid In Capital | $431,905,000 | $422,047,000 | $406,925,000 | $390,819,000 |
| Capital Stock | $1,068,000 | $1,057,000 | $1,040,000 | $1,024,000 |
| Common Stock | $1,068,000 | $1,057,000 | $1,040,000 | $1,024,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $16,487,000 | $17,170,000 | $17,969,000 | $15,938,000 |
| Current Deferred Revenue | $3,598,000 | $5,251,000 | $5,069,000 | $6,713,000 |
| Current Capital Lease Obligation | $1,456,000 | $864,000 | $774,000 | $157,000 |
| Current Accrued Expenses | $7,812,000 | $8,302,000 | $11,269,000 | $8,265,000 |
| Investments And Advances | $52,570,000 | $35,781,000 | $42,938,000 | $0 |
| Available For Sale Securities | $52,570,000 | $35,781,000 | $42,938,000 | - |
| Net PPE | $28,451,000 | $30,473,000 | $34,754,000 | $33,578,000 |
| Accumulated Depreciation | $-17,264,000 | $-13,592,000 | $-10,286,000 | $-6,275,000 |
| Gross PPE | $45,715,000 | $44,065,000 | $45,040,000 | $39,853,000 |
| Leases | $14,787,000 | $14,727,000 | $14,654,000 | $14,196,000 |
| Construction In Progress | $908,000 | $272,000 | $310,000 | $627,000 |
| Other Properties | $12,843,000 | $12,771,000 | $13,682,000 | $12,293,000 |
| Machinery Furniture Equipment | $17,177,000 | $16,295,000 | $16,394,000 | $12,737,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,182,000 | $3,927,000 | $5,977,000 | $2,930,000 |
| Work In Process | $501,000 | $270,000 | $558,000 | $0 |
| Raw Materials | $3,864,000 | $4,717,000 | $5,694,000 | $5,651,000 |
| Other Short Term Investments | $82,979,000 | $126,598,000 | $121,782,000 | $216,275,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-36,178,000 | $-29,261,000 | $-25,386,000 | $-33,260,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-34,410,000 | $-27,610,000 | $-21,686,000 | $-14,783,000 |
| Cash Flow From Continuing Operating Activities | $-34,410,000 | $-27,610,000 | $-21,686,000 | $-14,783,000 |
| Operating Gains Losses | $287,000 | $861,000 | $30,000 | $139,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,768,000 | $-1,651,000 | $-3,700,000 | $-18,477,000 |
| Investing Cash Flow | $25,935,000 | $6,932,000 | $54,984,000 | $-24,823,000 |
| Cash Flow From Continuing Investing Activities | $25,935,000 | $6,932,000 | $54,984,000 | $-24,823,000 |
| Financing Activities | ||||
| Financing Cash Flow | $656,000 | $2,056,000 | $2,143,000 | $2,888,000 |
| Cash Flow From Continuing Financing Activities | $656,000 | $2,056,000 | $2,143,000 | $2,888,000 |
| Issuance Of Capital Stock | - | - | $269,000 | $0 |
| Net Common Stock Issuance | - | - | $269,000 | $0 |
| Common Stock Issuance | - | - | $269,000 | $0 |
| Other | ||||
| End Cash Position | $20,065,000 | $27,884,000 | $46,506,000 | $11,065,000 |
| Beginning Cash Position | $27,884,000 | $46,506,000 | $11,065,000 | $47,783,000 |
| Changes In Cash | $-7,819,000 | $-18,622,000 | $35,441,000 | $-36,718,000 |
| Proceeds From Stock Option Exercised | $656,000 | $2,056,000 | $2,143,000 | $2,888,000 |
| Net Investment Purchase And Sale | $29,476,000 | $8,583,000 | $58,675,000 | $-6,346,000 |
| Sale Of Investment | $155,762,000 | $159,440,000 | $313,770,000 | $284,596,000 |
| Purchase Of Investment | $-126,286,000 | $-150,857,000 | $-255,095,000 | $-290,942,000 |
| Net Business Purchase And Sale | $-1,773,000 | $0 | - | - |
| Purchase Of Business | $-1,773,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-1,768,000 | $-1,651,000 | $-3,691,000 | $-18,477,000 |
| Purchase Of PPE | $-1,768,000 | $-1,651,000 | $-3,700,000 | $-18,477,000 |
| Change In Working Capital | $-6,124,000 | $-751,000 | $3,820,000 | $-3,977,000 |
| Change In Other Working Capital | $-1,678,000 | $182,000 | $-1,644,000 | $-34,000 |
| Change In Other Current Liabilities | $-1,193,000 | $-718,000 | $-172,000 | $6,353,000 |
| Change In Other Current Assets | $-724,000 | $-1,213,000 | $421,000 | $-492,000 |
| Change In Payables And Accrued Expense | $-3,721,000 | $-1,883,000 | $3,252,000 | $-150,000 |
| Change In Payable | $-3,721,000 | $-1,883,000 | $3,252,000 | $-150,000 |
| Change In Account Payable | $-3,721,000 | $-1,883,000 | $3,252,000 | $-150,000 |
| Change In Prepaid Assets | $-531,000 | $293,000 | $-641,000 | $320,000 |
| Change In Inventory | $575,000 | $1,362,000 | $-4,534,000 | $-3,493,000 |
| Change In Receivables | $1,148,000 | $1,226,000 | $7,138,000 | $-6,481,000 |
| Changes In Account Receivables | $1,148,000 | $1,226,000 | $7,138,000 | $-6,481,000 |
| Other Non Cash Items | $83,000 | $63,000 | $94,000 | $843,000 |
| Stock Based Compensation | $9,213,000 | $13,083,000 | $13,979,000 | $11,752,000 |
| Provisionand Write Offof Assets | $676,000 | $1,771,000 | $697,000 | $0 |
| Asset Impairment Charge | $3,589,000 | $-130,000 | $171,000 | $0 |
| Amortization Of Securities | $-2,646,000 | $-6,242,000 | $-7,120,000 | $-2,667,000 |
| Depreciation Amortization Depletion | $5,142,000 | $4,790,000 | $4,566,000 | $2,698,000 |
| Depreciation And Amortization | $5,142,000 | $4,790,000 | $4,566,000 | $2,698,000 |
| Depreciation | $5,142,000 | $4,790,000 | $4,566,000 | $2,698,000 |
| Gain Loss On Sale Of PPE | $287,000 | $861,000 | $30,000 | $139,000 |
| Net Income From Continuing Operations | $-44,630,000 | $-41,055,000 | $-37,923,000 | $-23,571,000 |
| Sale Of PPE | - | $0 | $9,000 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-22